You are here

Home » Content

TRANSREKTAL ULTRASONOGRAFİ EŞLİĞİNDE ALINAN PROSTAT BİYOPSİLERİNDE GLEASON 5 PATERNİ

GLEASON 5 PATERN WHO UNDERWENT TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2013

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Objectives: Prostate cancer is the most seen cancer in developed country and second reason of cancer related died in this population. We evalutaed the survival of the patients who had Gleason 5 patern on transrectal ultrasoun guided prostate biopsy. Material and Methods: The patients who had Gleason 5 patern underwent transrectal ultrasound guided prostate biopsy between 2005-2010 years included in the study. Seventy-six patients who were followed in our policilinic or died were recorded. Age at diagnosis, time of following, treatments, scores of Gleason, level of PSA’s at diagnosis and last were recorded. Results: Mean age of the patients, PSA levels, prostate volumes and following times are 69.4±8.6, 245.9±517.3 ng/ml, 57.2±30.6 cc and 38.8±12.3 months. Gleason 10,9,8 scores were detected in 6 (%7.9),68(%89.5) and 2(%2.6) patients.26 patients were treated surgical castration,44 patients were treated medical castration. Both radical prostatectomy and medical castration were performed on 6 patients. Twenty-two patients were treated with transurethral resection of prostate because of lower urinary tract symptoms. Eighteen patients died on following days mean time at 21.3±9.8 months. Conclusion: High grade prostate cancer is one of the major problems in daily practice. These patients progress to advanced stage because of the high Gleason score. High grade prostate cancer is one of the more common causes of cancer related death despite all treatments methods.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Prostat kanseri gelişmiş ülkelerdeki erkeklerde en sık görülen kanserdir ve bu popülasyonda mortalite riski açısından akciğer kanserlerinden sonra ikinci sırada yer almaktadır.Çalışmamızda prostat biyopsisinde Gleason patern skoru 5 rapor edilen hastaların sağ kalımları araştırıldı. Gereç ve Yöntem: Kliniğimizde 2005-2010 tarihleri arasında yapılan TRUS prostat biyopsilerinde, Gleason patern skoru 5 rapor edilen hastalar çalışmaya alındı. Takiplerine polikliniğimizde devam eden ya da eksitus gelişen 76 hasta verileri taranarak kaydedildi. Hastaların tanı yaşları, takip süreleri, aldıkları tedaviler, Gleason skorları, tanı anındaki PSA’ları ve son PSA’ları kaydedildi. Bulgular: Hastaların yaş ortalaması 69.4±8.6, PSA 245.9±517.3 ng/ml, prostat volümü 57.2±30.6 cc ve takip süresi 38.8±12.3 ay olarak hesaplandı. 6 hastada (%7.9) Gleason 10, 68 hastada (%89.5) Gleason 9 ve 2 hastada (%2.6) Gleason 8 tespit edildi. Hastaların aldıkları tedavi açısından bakıldığında 26 hastaya (%34.2) cerrahi kastrasyon, 44 hastaya (%57.9) medikal kastrasyon, 6 hastaya (%7.9) radikal prostatektomi ve sonrasında androjen blokajı uygulanmıştı. 22 olguya (%28.9) alt üriner sistem semptomları nedeni ile transuretral prostat rezeksiyonu yapılmıştı. 18 olguda (%23.7) ise takipler esnasında 21.3±9.8 ayda eksitus gözlenmiştir. Sonuç: Yüksek Gleason skorlu prostat kanseri hastaları klinikte karşımıza çıkan önemli sorunlardan biridir. Bu hastalar yüksek Gleason skoru nedeni ile daha kısa sürede metastatik evreye geçmektedir. Yüksek Gleason skorlu prostat kanserleri tüm tedavi yöntemlerine rağmen kansere bağlı ölümlerin sık görülen nedenlerinden biridir.
FULL TEXT (PDF): 
PDF icon 1.pdf
  • 1
1-3
  • Turkish

REFERENCES

References: 

1. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
2. Al-Hussain TO, Nagar MS, Epstein JI. Gleason Pattern 5 is Frequently Underdiagnosed on Prostate Needle-core Biopsy. Urology 2012;79:178-81.
3. Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995;154:460-5.
4. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 199;52:444-8.
5. Fidaner C, Eser SY, Parkin DM. Incidence in Izmir in 1993-1994: first results from Izmir Cancer Registry. Eur J Cancer 2001;37:83-92.
6. Gökçe A, Ergül G, Seçkin S. [Incidental prostate adenocarcinoma detected synchronously with bladder carcinoma: seven cases]. Turkiye Klinikleri J Med Sci 2008;28:967-71.
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
8. Mitsuyama H, Wallner K, Merrick G, Virgin J, Orio P, Montgomery B, et al. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy. Am J Clin Oncol 2007;30:597-600.
9. Nanda A, Chen MH, Renshaw AA, D'Amico AV. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009;74:1419-23.
10. Olacak N, Tavlayan E, Yalman D, Akagündüz Ö, Özkök S, Aras BA. [Comparision of 3, 4, 5, 6 and 7 –field therapy techniques in three dimensional conformal prostate radiotherapy]. Turkiye Klinikleri J Med Sci 2011;31:583-9.
11. Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000;24:563-9.
12. Polat K, Tüzel E, Aktepe F, Akdoğan B, Güler C, Uzun İ. [Investigation of the incidence of latent prostate cancer and high-grade prostatic intraepithelial neoplasia in an autopsy series of Turkish males]. Turkish Journal of Urology 2009;35:96-100.
13. Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011;81:e351-60.
14. Taş M, Kaygısız O, Inal G, Uğurlu Ö, Adsan Ö, Öztürk B. [Comparison of patient comfort and complications of transrectal ultrasonography guided prostate biopsies using 16 and 18 gauge needles]. Turkish Journal of Urology 2005;31: 119-122.
15. Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D, et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach. J Urol 2007;177:911-5.
16. Trpkov K, Zhang J, Chan M, Eigl BJ, Yilmaz A. Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopathologic findings and disease progression. Am J Surg Pathol 2009;33:233-40.
17. Uzunoğlu S, Karaca B, Atmaca H, Kısım A, Karabulut B, Uslu R. Targeting Bcl-2 protein to enhance chemosensitivity of hormone refractory prostate cancer cell line, DU-145 by a synergistic combination of docetaxel and gossypol. Turkiye Klinikleri J Med Sci 2011;31:859-66.

Thank you for copying data from http://www.arastirmax.com